311 related articles for article (PubMed ID: 16155794)
1. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
Schott AF; Roubidoux MA; Helvie MA; Hayes DF; Kleer CG; Newman LA; Pierce LJ; Griffith KA; Murray S; Hunt KA; Paramagul C; Baker LH
Breast Cancer Res Treat; 2005 Aug; 92(3):231-8. PubMed ID: 16155794
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
[TBL] [Abstract][Full Text] [Related]
4. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy.
Bodini M; Berruti A; Bottini A; Allevi G; Fiorentino C; Brizzi MP; Bersiga A; Generali D; Volpi D; Marini U; Aguggini S; Tampellini M; Alquati P; Olivetti L; Dogliotti L
Breast Cancer Res Treat; 2004 Jun; 85(3):211-8. PubMed ID: 15111758
[TBL] [Abstract][Full Text] [Related]
6. Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer--clinical examination, mammography, or magnetic resonance imaging?
Wright FC; Zubovits J; Gardner S; Fitzgerald B; Clemons M; Quan ML; Causer P
J Surg Oncol; 2010 Jun; 101(7):604-10. PubMed ID: 20461768
[TBL] [Abstract][Full Text] [Related]
7. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of mammography, ultrasonography and magnetic resonance imaging in the detection of intraductal spread of breast cancer following neoadjuvant chemotherapy.
Kubota K; Ogawa Y; Nishioka A; Kariya S; Itoh S; Murata Y; Hamada N; Maeda H; Tanaka Y
Oncol Rep; 2007 Apr; 17(4):915-8. PubMed ID: 17342336
[TBL] [Abstract][Full Text] [Related]
10. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
[TBL] [Abstract][Full Text] [Related]
12. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
[TBL] [Abstract][Full Text] [Related]
13. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
14. Breast conservation after induction chemotherapy for locally advanced breast cancer.
Kling KM; Ostrzega N; Schmit P
Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
[TBL] [Abstract][Full Text] [Related]
15. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Loibl S; von Minckwitz G; Raab G; Blohmer JU; Dan Costa S; Gerber B; Eidtmann H; Petrich S; Hilfrich J; Jackisch C; du Bois A; Kaufmann M
Ann Surg Oncol; 2006 Nov; 13(11):1434-42. PubMed ID: 16983592
[TBL] [Abstract][Full Text] [Related]
16. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study.
Bollet MA; Thibault F; Bouillon K; Meunier M; Sigal-Zafrani B; Savignoni A; Diéras V; Nos C; Salmon R; Fourquet A;
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):13-8. PubMed ID: 17449193
[TBL] [Abstract][Full Text] [Related]
17. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
Cooper BW; Radivoyevitch T; Overmoyer BA; Shenk RR; Pham HT; Samuels JR; Parry MP; Silverman P
Breast Cancer Res Treat; 2006 Jun; 97(3):311-8. PubMed ID: 16344915
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
